Gerald L. Messerschmidt

Author

Also Known As

G L Messerschmidt, G Messerschmidt, G. L. Messerschmidt, G.L. Messerschmidt, GERALD L. MESSERSCHMIDT, Gerald L Messerschmidt, Gerald L. Messerschmidt, Gerald Messerschmidt

Publications

750

Citations

H-Index

Concepts

All Affiliations

Wilford Hall Ambulatory Surgical Center National Cancer Institute Graduate Hospital United States Air Force Mitre (United States)

About

Gerald L. Messerschmidt is an author at Wilford Hall Ambulatory Surgical Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	486
2	Health Sciences	4	4	220
3	Allergy	1	1	21
4	Blood Transplantation	1	1	27
5	Cell Biology	1	1	21

Gerald L. Messerschmidt

Publications

593

Citations

H-Index

Page 1

	Year	Citations
Treatment of poor prognosis nonseminomatous testicular cancer with a “high-dose” platinum combination chemotherapy regimen Robert F. Ozols, Albert Deisseroth, Nasser Javadpour, Cancer Cancer ManagementPathologyPharmacotherapyMetronomic ChemotherapyTesticular Tumours	1983	145
Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma Harry W. Snyder, A Mittelman, Gerald L. Messerschmidt, Cancer	1993	107
Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer Joseph P. Balint, Elizabeth S. Gabitzsch, Adrian Rice, Cancer Immunology Immunotherapy Phase 1/2Extended EvaluationMedicineImmunologyColorectal Cancer	2015	53
Protein A immunoadsorption in the treatment of malignant disease. Gerald L. Messerschmidt, David H. Henry, Harry W. Snyder, Journal of Clinical Oncology Immune EvasionCancer ImmunosurveillanceMalignant DiseaseImmunologyTumor Immunity	1988	51
Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma Richard Leff, James Thompson, Mary B. Daly, Cancer PharmacotherapyHigh-grade GliomasBrain LesionGliomaNeuro-oncology	1988	48
Recurrent hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in hodgkin's disease Richard J. Mercier, James Thompson, G. S. Harman, The American Journal of Medicine MedicineClinical NutritionPathologyRecurrent Hypercalcemia	1988	39
Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma. Richard Leff, J M Thompson, David B. Johnson, Journal of Clinical Oncology Median DurationImmunologySurgeryMetronomic ChemotherapyHigh-dose Melphalan	1986	36
A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients Gerald L. Messerschmidt, Robert Makuch, F R Appelbaum, Cancer PathologyHla-matched VersusCancer PatientsImmunotherapyPlatelet Transfusion	1988	27
Minimal toxicity during protein a immunoadsorption treatment of malignant disease: An outpatient therapy Harry W. Snyder, David H. Henry, Gerald L. Messerschmidt, Journal of Clinical Apheresis ImmunologyImmunoeditingPathologyMetronomic ChemotherapyImmunotherapy	1991	23
T CELL DEPLETION OF HUMAN BONE MARROW USING MONOCLONAL ANTIBODY AND COMPLEMENT-MEDIATED LYSIS Thomas G. Sharp, David H. Sachs, Anthony S. Fauci, Transplantation Cell TherapyBone Marrow FailureAutoimmune DiseaseAllergyLaboratory Hematology	1983	21

Page 1